Good morning, you're listening to Markets Desk.
ProMIS Neurosciences is moving on promising clinical data this morning. Its lead Alzheimer's candidate, PMN three ten, showed the first human evidence of a dose-dependent reduction in amyloid-beta oligomers — the toxic protein clusters at the heart of the disease. That's a meaningful early signal for a space starved of genuine target engagement data.
Shifting to luxury retail, Watches of Switzerland posted a significant profit surge in fiscal twenty twenty six, carried by solid revenue growth across its high-end watch and jewellery portfolio. The company is backing a positive outlook for fiscal twenty twenty seven, though investors should note adjusted margins did compress year over year — a tension worth watching as discretionary spending remains under pressure globally.
And on the energy front, a striking new analysis finds that data center expansion has already pushed electricity costs on American ratepayers up by twenty three billion dollars. With major tech firms pledging to cover their fair share, the critical question is how those costs get allocated — and whether utility regulators can enforce accountability before the bill grows further.
That's the tape. Markets Desk, signing off the floor.
